PriceTargets.com logo

Insmed - INSM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.27
  • Forecasted Upside: 73.41%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$23.80 As of 11/28/2023 05:29 PM ET
▼ -0.14 (-0.58%)

This chart shows the closing price for INSM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Insmed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INSM

Analyst Price Target is $41.27
▲ +73.41% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $41.27, with a high forecast of $52.00 and a low forecast of $28.00. The average price target represents a 73.41% upside from the last price of $23.80.

This chart shows the closing price for INSM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 contributing investment analysts is to buy stock in Insmed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/30/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2023JPMorgan Chase & Co.Reiterated RatingOverweight$36.00Low
9/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$46.00Low
9/7/2023Evercore ISIBoost TargetOutperform ➝ Outperform$32.00 ➝ $42.00Low
9/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$52.00Low
9/6/2023Bank of AmericaBoost TargetBuy ➝ Buy$35.00 ➝ $37.00Low
9/5/2023GuggenheimBoost TargetBuy ➝ Buy$50.00 ➝ $52.00Low
8/4/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$41.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$52.00Low
7/25/2023GuggenheimInitiated CoverageBuy$50.00Low
2/24/2023HC WainwrightReiterated RatingBuy$52.00Low
2/24/2023Credit Suisse GroupReiterated RatingOutperform$46.00N/A
2/24/2023Cantor FitzgeraldLower TargetOverweight$49.00 ➝ $46.00Low
1/20/2023BarclaysLower TargetOverweight$37.00 ➝ $35.00Low
1/9/2023The Goldman Sachs GroupLower TargetBuy$44.00 ➝ $39.00Low
12/8/2022MizuhoInitiated CoverageBuy$28.00Low
12/7/2022BarclaysInitiated CoverageOverweight$37.00Low
11/28/2022JPMorgan Chase & Co.Lower Target$38.00Low
11/18/2022Bank of AmericaInitiated CoverageBuy$39.00Low
11/1/2022Credit Suisse GroupLower Target$52.00Low
10/27/2022SVB LeerinkLower TargetOutperform$52.00 ➝ $50.00Low
10/25/2022Cantor FitzgeraldLower TargetOverweight$53.00 ➝ $49.00Low
10/21/2022CowenLower TargetOutperform$56.00 ➝ $53.00Low
10/21/2022CowenLower TargetOutperform$56.00 ➝ $53.00Low
8/9/2022Credit Suisse GroupBoost Target$58.00Low
7/15/2022Morgan StanleyLower TargetOverweight$46.00 ➝ $41.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$56.00 ➝ $48.00Low
4/27/2022The Goldman Sachs GroupInitiated CoverageBuy$56.00Low
2/22/2022SVB LeerinkLower TargetOutperform$57.00 ➝ $52.00Low
12/6/2021JPMorgan Chase & Co.Initiated CoverageOverweight$45.00High
10/8/2021HC WainwrightReiterated RatingBuy$52.00Low
10/8/2021Cantor FitzgeraldInitiated CoverageOverweight$60.00Low
5/10/2021Morgan StanleyLower TargetOverweight$58.00 ➝ $56.00High
3/2/2021Morgan StanleyBoost TargetOverweight$55.00 ➝ $58.00Medium
1/19/2021Credit Suisse GroupBoost TargetOutperform$50.00 ➝ $60.00High
1/4/2021SVB LeerinkBoost TargetOutperform$51.00 ➝ $55.00N/A
12/17/2020Berenberg BankInitiated CoverageBuy$48.00Medium
12/16/2020Morgan StanleyBoost TargetOverweight$42.00 ➝ $55.00High
11/23/2020Evercore ISIReiterated RatingOutperform$60.00Low
11/11/2020Morgan StanleyBoost TargetOverweight$38.00 ➝ $42.00High
10/12/2020Stifel NicolausInitiated CoverageBuy$44.00Medium
8/10/2020Morgan StanleyBoost TargetOverweight$35.00 ➝ $38.00Medium
6/25/2020HC WainwrightReiterated RatingBuy$52.00High
5/1/2020HC WainwrightReiterated RatingBuy$52.00High
4/15/2020Morgan StanleyLower TargetOverweight$50.00 ➝ $35.00Low
3/17/2020Stifel NicolausLower TargetBuy$55.00 ➝ $45.00High
3/17/2020Credit Suisse GroupLower TargetOutperform$49.00 ➝ $42.00Medium
2/4/2020HC WainwrightReiterated RatingBuy$52.00Medium
2/4/2020The Goldman Sachs GroupBoost TargetBuy$33.00 ➝ $46.00High
2/4/2020Morgan StanleyBoost TargetOverweight$37.00 ➝ $50.00High
1/15/2020JMP SecuritiesReiterated RatingBuy$40.00High
1/6/2020CowenReiterated RatingBuy$56.00High
1/2/2020Credit Suisse GroupReiterated RatingOutperform$40.00 ➝ $40.00Medium
11/1/2019Morgan StanleySet TargetBuy$37.00Low
10/31/2019HC WainwrightReiterated RatingBuyLow
9/10/2019Credit Suisse GroupReiterated RatingBuy$40.00Medium
9/3/2019The Goldman Sachs GroupInitiated CoverageBuy$30.00High
4/9/2019HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $52.00Medium
2/15/2019JMP SecuritiesUpgradeMarket Perform ➝ Outperform$40.00Medium
1/17/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$29.00 ➝ $35.00High
12/4/2018CitigroupLower TargetNeutral ➝ Neutral$29.00 ➝ $22.00High
(Data available from 11/28/2018 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2023
  • 6 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
6/1/2023
  • 9 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2023
  • 7 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2023
  • 7 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/30/2023
  • 16 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Insmed logo
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Read More

Today's Range

Now: $23.80
Low: $23.55
High: $24.11

50 Day Range

MA: $24.82
Low: $23.42
High: $26.34

52 Week Range

Now: $23.80
Low: $16.04
High: $27.59

Volume

888,457 shs

Average Volume

1,232,576 shs

Market Capitalization

$3.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Insmed?

The following sell-side analysts have issued reports on Insmed in the last year: Bank of America Co., Barclays PLC, Cantor Fitzgerald, Credit Suisse Group AG, Evercore ISI, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for INSM.

What is the current price target for Insmed?

11 Wall Street analysts have set twelve-month price targets for Insmed in the last year. Their average twelve-month price target is $41.27, suggesting a possible upside of 73.4%. Guggenheim has the highest price target set, predicting INSM will reach $52.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $28.00 for Insmed in the next year.
View the latest price targets for INSM.

What is the current consensus analyst rating for Insmed?

Insmed currently has 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INSM will outperform the market and that investors should add to their positions of Insmed.
View the latest ratings for INSM.

What other companies compete with Insmed?

Other companies that are similar to Insmed include Nuvalent, Evotec, ACADIA Pharmaceuticals, Madrigal Pharmaceuticals and Amicus Therapeutics. Learn More about companies similar to Insmed.

How do I contact Insmed's investor relations team?

Insmed's physical mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company's listed phone number is 908-977-9900 and its investor relations email address is in[email protected]. The official website for Insmed is www.insmed.com. Learn More about contacing Insmed investor relations.